% ============================================================================
% CONSTRAINT STORY: fmt_oncology_realignment_2026
% ============================================================================
% Version: 3.4 (Deferential Realism Core)
% Logic: 3.3 (Indexed Tuple P,T,E,S)
% Generated: 2026-02-06
% ============================================================================

:- module(constraint_fmt_oncology_2026, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    constraint_indexing:constraint_classification/3.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 * * constraint_id: fmt_oncology_2026
 * human_readable: FMT Immunotherapy Realignment
 * domain: health/medical
 * * SUMMARY:
 * New Phase I and II trials released in late January 2026 indicate that oral 
 * fecal microbiota transplantation (FMT) pills can reduce immunotherapy 
 * toxicity and significantly improve cancer response rates. 
 * By using healthy gut bacteria as a template, this approach transforms a 
 * dysfunctional microbiome "Snare" into a "Rope" for surviving late-stage 
 * kidney, lung, and melanoma cancers.
 * * KEY AGENTS:
 * - Cancer Patients (Metastatic/Advanced): Subject (Powerless)
 * - Research Institutes (Lawson/LHSCRI/Montreal): Beneficiary (Institutional)
 * - Medical Journalists (Ed Cara): Auditor (Analytical)
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% Extraction is low (0.18). The shift to oral pills reduces the "extraction" 
% of patient comfort and resource-intensive colonoscopies.
domain_priors:base_extractiveness(fmt_oncology_2026, 0.18). 

% Suppression is moderate (0.45). The framework suppresses the negative 
% side effects of immunotherapy, such as nausea and diarrhea.
domain_priors:suppression_score(fmt_oncology_2026, 0.45).   

% Theater ratio is low (0.12) as the results show functional improvements 
% in clinical response rates (75-80%) over standard treatments.
domain_priors:theater_ratio(fmt_oncology_2026, 0.12).       

% Constraint metric facts (bridge for classification engine)
narrative_ontology:constraint_metric(fmt_oncology_2026, extractiveness, 0.18).
narrative_ontology:constraint_metric(fmt_oncology_2026, suppression_requirement, 0.45).
narrative_ontology:constraint_metric(fmt_oncology_2026, theater_ratio, 0.12).

% Primary keys for the classification engine
% High-fidelity stakeholders
narrative_ontology:constraint_beneficiary(fmt_oncology_2026, oncological_microbiome_research).
narrative_ontology:constraint_victim(fmt_oncology_2026, standard_immunotherapy_limitations).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: THE PATIENT (SNARE)
% Previously, late-stage cancer patients faced a Snare: a dysfunctional 
% microbiome that either resisted immunotherapy or increased its toxicity 
% .
constraint_indexing:constraint_classification(fmt_oncology_2026, snare, 
    context(agent_power(powerless), 
            time_horizon(biographical), 
            exit_options(trapped), 
            spatial_scope(national))).

% PERSPECTIVE 2: THE CLINICIAN (ROPE)
% Researchers view oral FMT as a Rope: a coordination tool to rebuild 
% the microbiome and boost natural immune defenses.
constraint_indexing:constraint_classification(fmt_oncology_2026, rope, 
    context(agent_power(institutional), 
            time_horizon(generational), 
            exit_options(mobile), 
            spatial_scope(global))).

% PERSPECTIVE 3: THE ANALYTICAL OBSERVER (SCAFFOLD)
% Analysts view this as a Scaffold: a transitional "boon" to immunotherapy 
% until personalized microbial blueprints are fully mapped.
constraint_indexing:constraint_classification(fmt_oncology_2026, scaffold,
    context(agent_power(analytical),
            time_horizon(historical),
            exit_options(analytical),
            spatial_scope(global))) :-
    narrative_ontology:has_sunset_clause(fmt_oncology_2026).

% Mandatory sunset clause for the transitional Phase II research period.
narrative_ontology:has_sunset_clause(fmt_oncology_2026).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(fmt_oncology_2026_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(fmt_oncology_2026, snare, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(fmt_oncology_2026, rope, context(agent_power(institutional), _, _, _)).

test(response_rate_fidelity) :-
    domain_priors:theater_ratio(fmt_oncology_2026, TR),
    TR < 0.20.

:- end_tests(fmt_oncology_2026_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 * The extraction score (0.18) is low because oral pills replace invasive 
 * enemas/colonoscopies. The response rate of 75-80% for lung 
 * cancer and melanoma patients validates the framework as a functional 
 * clinical Rope rather than a theatrical mask.
 *
 * * MANDATROPHY ANALYSIS:
 * [RESOLVED MANDATROPHY]
 * The system identifies the "Sovereignty Gap" in cancer care where patients 
 * who otherwise wouldn't respond to standard care gain a new survival 
 * pathway through the oral pill format.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Î©) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    omega_microbial_personalization,
    'Can customized FMT pills be scaled for general late-stage cancer treatment?',
    'Review of ongoing large-scale trials and quality of life Statement.',
    'Success secures the global Rope; failure returns the patient to the Snare.',
    confidence_without_resolution(medium)
).

/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(fmt_oncology_2026, 0, 10).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Modeling the drift from "Invasive FMT" to "Oral Poop Pills."
% Theater ratio drops as clinical evidence replaces early experimental hype.
narrative_ontology:measurement(fmt_tr_t0, fmt_oncology_2026, theater_ratio, 0, 0.45).
narrative_ontology:measurement(fmt_tr_t5, fmt_oncology_2026, theater_ratio, 5, 0.25).
narrative_ontology:measurement(fmt_tr_t10, fmt_oncology_2026, theater_ratio, 10, 0.12).

% Extraction drops as patient drug toxicity and side effects are reduced.
narrative_ontology:measurement(fmt_ex_t0, fmt_oncology_2026, base_extractiveness, 0, 0.40).
narrative_ontology:measurement(fmt_ex_t5, fmt_oncology_2026, base_extractiveness, 5, 0.28).
narrative_ontology:measurement(fmt_ex_t10, fmt_oncology_2026, base_extractiveness, 10, 0.18).

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
